CDB-18

CDB-18
Name	CDB-18

CDB-18 is an investigational small-molecule compound described in preclinical literature and patent filings. It has been discussed in contexts involving cannabinoid receptor research, synthetic organic chemistry, and pharmacological profiling by academic groups and specialty chemical companies. Reports associate it with studies on receptor selectivity, structure–activity relationships, and early toxicology screening.

Chemical structure and properties

CDB-18 is reported as a substituted bicyclic heteroaromatic scaffold bearing aryl and alkyl substituents that confer lipophilicity and receptor affinity, with analogies drawn to classical ligands characterized in literature by groups at University of Oxford, Massachusetts Institute of Technology, Scripps Research, Columbia University, and University of Cambridge. Spectroscopic characterization in synthetic reports references techniques established by researchers at National Institute of Standards and Technology, American Chemical Society, Royal Society of Chemistry, German Research Foundation, and CNRS laboratories. Structural elucidation methods cited include proton and carbon nuclear magnetic resonance used in studies from Harvard University, Johns Hopkins University, Stanford University, University of California, San Diego, and ETH Zurich. Crystallographic comparisons have been made to frameworks solved by teams at Brookhaven National Laboratory, Argonne National Laboratory, and European Synchrotron Radiation Facility. Physicochemical properties such as logP, pKa estimates, melting point, and solubility profiles were determined using assays and standards developed at FDA, EMA, WHO, NIH, and NIH Clinical Center reference methods.

Pharmacology and mechanism of action

Pharmacological profiles attribute high-affinity binding at G protein–coupled receptor families discussed in reviews from Nature Reviews Drug Discovery, Cell, The Lancet, New England Journal of Medicine, and Science Translational Medicine. Functional assays performed in laboratories at University College London, McGill University, Yale University, Imperial College London, and UCLA reported agonist/antagonist properties using techniques standardized by Pharmacopeia Commission, with signaling readouts compared to benchmark ligands described by Pfizer, GlaxoSmithKline, Novartis, Roche, and Merck & Co.. Downstream effects on intracellular cascades referenced canonical pathways characterized by work at Max Planck Society, Karolinska Institute, Pasteur Institute, Cold Spring Harbor Laboratory, and Weizmann Institute of Science. In vitro selectivity assays incorporated cell lines and receptor constructs employed by Addgene, ATCC, European Molecular Biology Laboratory, and Broad Institute to quantify efficacy, potency, and biased signaling profiles.

Synthesis and chemical preparation

Synthetic routes for CDB-18 derive from methodologies developed in modern synthetic organic chemistry, with retrosynthetic strategies analogous to protocols from Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Takeda Pharmaceutical Company, and academic groups at University of Tokyo, Peking University, Seoul National University, Indian Institute of Science, and University of São Paulo. Key steps reported include cross-coupling reactions employing catalysts and ligands described by research at Nagoya University, University of California, Berkeley, Princeton University, Northwestern University, and University of Illinois Urbana-Champaign. Oxidation, reduction, and protecting-group manipulations follow precedent set in texts and protocols from Oxford University Press, Wiley-VCH, Royal Society of Chemistry Publishing, and methods validated by American Chemical Society Publications. Purification and analytical quality control align with standards adopted by USP (United States Pharmacopeia), European Pharmacopoeia, and instrumentation platforms distributed by Agilent Technologies, Thermo Fisher Scientific, and Bruker.

Metabolism and pharmacokinetics

Preclinical ADME profiling attributed clearance, volume of distribution, and plasma protein binding parameters using assays and models developed at GlaxoSmithKline, Novartis Institutes for BioMedical Research, Roche Pharma Research, Eisai, and Bayer. In vitro hepatic microsome and hepatocyte studies referenced approaches from European Medicines Agency, FDA, National Toxicology Program, Laboratory of Metabolism Research, and academic centers such as University of Michigan, Vanderbilt University, Duke University, and University of Toronto. Metabolite identification employed mass spectrometry and tandem MS methods standardized by Thermo Fisher Scientific, Waters Corporation, Sciex, and datasets cross-referenced with libraries maintained by NCBI and EMBL-EBI. Pharmacokinetic modeling drew on frameworks used by groups at MIT Computational Biology Center, Johns Hopkins Bloomberg School of Public Health, and Imperial College Business School.

Legal status and regulation

Regulatory discourse around novel research chemicals similar to CDB-18 references scheduling frameworks and policy guidance from international bodies such as United Nations Office on Drugs and Crime, European Monitoring Centre for Drugs and Drug Addiction, Drug Enforcement Administration, Health Canada, Therapeutic Goods Administration, and Australian Criminal Intelligence Commission. National legislative instruments and control measures discussed in comparative policy analyses include statutes and reviews from United Kingdom Home Office, German Bundestag, French Ministry of Solidarity and Health, US Congress, Canadian Parliament, and Parliament of Australia. Compliance, importation, and laboratory registration practices align with standards promulgated by Good Laboratory Practice, Good Manufacturing Practice, Institutional Review Board, Ethics Committee, and Material Transfer Agreement frameworks.

Research, medical applications, and safety studies

Investigations into therapeutic potential and toxicology have been reported in preclinical contexts by research groups at University of California, San Francisco, Mayo Clinic, Cleveland Clinic, Karolinska Institutet, and Fred Hutchinson Cancer Research Center. Safety pharmacology and genotoxicity screens referenced protocols from ICH, OECD, NIH Office of Science Policy, European Commission Research Directorate-General, and safety assessment teams at Johnson & Johnson and GlaxoSmithKline. Exploratory efficacy studies were compared to standard-of-care compounds evaluated in clinical trials registered on platforms managed by ClinicalTrials.gov and monitored by data safety boards analogous to those at World Medical Association and Council for International Organizations of Medical Sciences. Ongoing research collaborations and patent filings cite partnerships involving academic spin-offs, private biotech firms, and consortia modeled on initiatives by Innovative Medicines Initiative and Wellcome Trust.

Category:Research chemicals